Citigroup
ZNTL icon

Citigroup’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Citigroup’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$181K Buy
+77,255
New +$200K ﹤0.01% 4046
2025
Q4 		– Sell
-906
Closed -$1.37K – 6538
2025
Q3 		$1.37K Sell
906
-18,541
-95% -$27.8K ﹤0.01% 5578
2025
Q2 		$22.6K Sell
19,447
-21,199
-52% -$28K ﹤0.01% 5045
2025
Q1 		$64.6K Sell
40,646
-4,855
-11% -$10.5K ﹤0.01% 4803
2024
Q4 		$138K Buy
45,501
+1,815
+4% +$5.95K ﹤0.01% 4663
2024
Q3 		$161K Sell
43,686
-240
-0.5% -$872 ﹤0.01% 4496
2024
Q2 		$180K Sell
43,926
-213,161
-83% -$2.38M ﹤0.01% 3944
2024
Q1 		$4.05M Buy
257,087
+111,169
+76% +$1.53M ﹤0.01% 1871
2023
Q4 		$2.21M Buy
145,918
+60,713
+71% +$886K ﹤0.01% 2156
2023
Q3 		$1.71M Sell
85,205
-202
-0.2% -$5.13K ﹤0.01% 2100
2023
Q2 		$2.41M Sell
85,407
-103,312
-55% -$2.48M ﹤0.01% 2030
2023
Q1 		$3.25M Buy
188,719
+86,785
+85% +$1.76M ﹤0.01% 1720
2022
Q4 		$2.05M Sell
101,934
-66,881
-40% -$1.44M ﹤0.01% 2016
2022
Q3 		$3.66M Buy
168,815
+37,965
+29% +$1.04M ﹤0.01% 1730
2022
Q2 		$3.68M Buy
130,850
+99,406
+316% +$2.63M ﹤0.01% 1710
2022
Q1 		$1.45M Sell
31,444
-30,220
-49% -$1.63M ﹤0.01% 2622
2021
Q4 		$5.18M Buy
61,664
+27,830
+82% +$2.15M ﹤0.01% 1804
2021
Q3 		$2.25M Sell
33,834
-42,731
-56% -$2.47M ﹤0.01% 2449
2021
Q2 		$4.07M Sell
76,565
-5,807
-7% -$311K ﹤0.01% 2076
2021
Q1 		$3.57M Buy
82,372
+70,352
+585% +$3.03M ﹤0.01% 2064
2020
Q4 		$625K Buy
12,020
+11,455
+2,027% +$517K ﹤0.01% 4006
2020
Q3 		$18K Sell
565
-841
-60% -$29.4K ﹤0.01% 6280
2020
Q2 		$68K Buy
+1,406
New +$53.9K ﹤0.01% 5846

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Citigroup's ZNTL Position: Q1 2026 in Review

Citigroup opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 77,255 shares worth $181K. The stake represents ﹤0.01% of the portfolio and ranks #4046 among its holdings. This is a return to the name: Citigroup previously reported a position in ZNTL as recently as Q3 2025.

Citigroup first reported a position in ZNTL in Q2 2020 and has held it in 23 quarters since. The position peaked at $5.18M in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Citigroup held 77,255 shares of Zentalis Pharmaceuticals worth $181K as of Q1 2026.
  • Zentalis Pharmaceuticals was a new Citigroup position in Q1 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4046 holding.
  • Citigroup first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Citigroup's Zentalis Pharmaceuticals position peaked at $5.18M in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.